TY - JOUR
T1 - Association of Dietary, Circulating, and Supplement Fatty Acids With Coronary Risk A Systematic Review and Meta-analysis
AU - Chowdhury, R
AU - Warnakula, S
AU - Kunutsor, S
AU - Crowe, F
AU - Ward, HA
AU - Johnson, L
AU - Franco Duran, OH
AU - Butterworth, AS
AU - Forouhi, NG
AU - Thompson, SG
AU - Khaw, KT
AU - Mozaffarian, D
AU - Danesh, J
AU - Di Angelantonio, E
PY - 2014
Y1 - 2014
N2 - Background: Guidelines advocate changes in fatty acid consumption to promote cardiovascular health. Purpose: To summarize evidence about associations between fatty acids and coronary disease. Data Sources: MEDLINE, Science Citation Index, and Cochrane Central Register of Controlled Trials through July 2013. Study Selection: Prospective, observational studies and randomized, controlled trials. Data Extraction: Investigators extracted data about study characteristics and assessed study biases. Data Synthesis: There were 32 observational studies (512 420 participants) of fatty acids from dietary intake; 17 observational studies (25 721 participants) of fatty acid biomarkers; and 27 randomized, controlled trials (105 085 participants) of fatty acid supplementation. In observational studies, relative risks for coronary disease were 1.03 (95% CI, 0.98 to 1.07) for saturated, 1.00 (CI, 0.91 to 1.10) for monounsaturated, 0.87 (CI, 0.78 to 0.97) for long-chain omega-3 polyunsaturated, 0.98 (CI, 0.90 to 1.06) for omega-6 polyunsaturated, and 1.16 (CI, 1.06 to 1.27) for trans fatty acids when the top and bottom thirds of baseline dietary fatty acid intake were compared. Corresponding estimates for circulating fatty acids were 1.06 (CI, 0.86 to 1.30), 1.06 (CI, 0.97 to 1.17), 0.84 (CI, 0.63 to 1.11), 0.94 (CI, 0.84 to 1.06), and 1.05 (CI, 0.76 to 1.44), respectively. There was heterogeneity of the associations among individual circulating fatty acids and coronary disease. In randomized, controlled trials, relative risks for coronary disease were 0.97 (CI, 0.69 to 1.36) for alpha-linolenic, 0.94 (CI, 0.86 to 1.03) for long-chain omega-3 polyunsaturated, and 0.86 (CI, 0.69 to 1.07) for omega-6 polyunsaturated fatty acid supplementations. Limitation: Potential biases from preferential publication and selective reporting. Conclusion: Current evidence does not clearly support cardiovascular guidelines that encourage high consumption of polyunsaturated fatty acids and low consumption of total saturated fats.
AB - Background: Guidelines advocate changes in fatty acid consumption to promote cardiovascular health. Purpose: To summarize evidence about associations between fatty acids and coronary disease. Data Sources: MEDLINE, Science Citation Index, and Cochrane Central Register of Controlled Trials through July 2013. Study Selection: Prospective, observational studies and randomized, controlled trials. Data Extraction: Investigators extracted data about study characteristics and assessed study biases. Data Synthesis: There were 32 observational studies (512 420 participants) of fatty acids from dietary intake; 17 observational studies (25 721 participants) of fatty acid biomarkers; and 27 randomized, controlled trials (105 085 participants) of fatty acid supplementation. In observational studies, relative risks for coronary disease were 1.03 (95% CI, 0.98 to 1.07) for saturated, 1.00 (CI, 0.91 to 1.10) for monounsaturated, 0.87 (CI, 0.78 to 0.97) for long-chain omega-3 polyunsaturated, 0.98 (CI, 0.90 to 1.06) for omega-6 polyunsaturated, and 1.16 (CI, 1.06 to 1.27) for trans fatty acids when the top and bottom thirds of baseline dietary fatty acid intake were compared. Corresponding estimates for circulating fatty acids were 1.06 (CI, 0.86 to 1.30), 1.06 (CI, 0.97 to 1.17), 0.84 (CI, 0.63 to 1.11), 0.94 (CI, 0.84 to 1.06), and 1.05 (CI, 0.76 to 1.44), respectively. There was heterogeneity of the associations among individual circulating fatty acids and coronary disease. In randomized, controlled trials, relative risks for coronary disease were 0.97 (CI, 0.69 to 1.36) for alpha-linolenic, 0.94 (CI, 0.86 to 1.03) for long-chain omega-3 polyunsaturated, and 0.86 (CI, 0.69 to 1.07) for omega-6 polyunsaturated fatty acid supplementations. Limitation: Potential biases from preferential publication and selective reporting. Conclusion: Current evidence does not clearly support cardiovascular guidelines that encourage high consumption of polyunsaturated fatty acids and low consumption of total saturated fats.
U2 - 10.7326/M13-1788
DO - 10.7326/M13-1788
M3 - Article
C2 - 24723079
SN - 0003-4819
VL - 160
SP - 398-+
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
IS - 6
ER -